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Abstract
Background: We have recently reported that human bone marrow-derived mesenchymal stem cells (MSCs)
facilitate angiogenesis and prevent follicle loss in xenografted human ovarian tissues. However, the mechanism
underlying this effect remains to be elucidated. Thus, determining the paracrine profiles and identifying the key
secreted factors in MSCs co-transplanted with ovarian grafts are essential for the future application of MSCs.
Methods: In this study, we used cytokine microarrays to identify differentially expressed proteins associated with
angiogenesis in frozen-thawed ovarian tissues co-transplanted with MSCs. The function of specific secreted factors
in MSCs co-transplanted with human ovarian tissues was studied via targeted blockade with short-hairpin RNAi and
the use of monoclonal neutralizing antibodies.
Results: Our results showed that angiogenin (ANG) was one of the most robustly up-regulated proteins (among
42 protein we screened, 37 proteins were up-regulated). Notably, the targeted depletion of ANG with short-hairpin
RNAi (shANG) or the addition of anti-ANG monoclonal neutralizing antibodies (ANG Ab) significantly reversed the
MSC-stimulated angiogenesis, increased follicle numbers and protective effect on follicle apoptosis.
Conclusion: Our results indicate that ANG plays a critical role in regulating angiogenesis and follicle survival in
xenografted human ovarian tissues. Our findings provide important insights into the molecular mechanism by
which MSCs promote angiogenesis and follicle survival in transplanted ovarian tissues, thus providing a theoretical
basis for their further application.
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Background
The transplantation of frozen-thawed ovarian tissue is a
promising technique for the restoration of endocrine
function and fertility [1], especially in cancer patients
who have undergone gonadotoxic therapy [2–6]. How-
ever, ischemia-reperfusion injury and insufficient re-
vascularization following transplantation, which lead to
failure of follicular survival, are significant obstacles to
the wider application of this technique [7–9]. Therefore,
searching for methods to minimize this damage and to
induce adequate revascularization is a critical step for
successful ovarian tissue transplantation and the preser-
vation of fertility.
Mesenchymal stem cells (MSCs), which can be isolated
from various tissues [10], are a population of cells pos-
sessing pluripotent capabilities. MSCs have been shown
to be a promising therapeutic approach to treat a
spectrum of diseases, especially in disorders associated
with insufficient angiogenesis [11, 12]. Recently, we
demonstrated that MSCs from human bone marrow
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functioned as a supportive agent for human ovarian
tissue transplantation, promoting angiogenesis and fol-
licle survival [13]. However, the mechanism underlying
this process is unknown. A better understanding of how
co-transplanted MSCs exert their pro-angiogenic effects
on ovarian grafts can help optimize the parameters for
clinical applications. Therefore, in this study, we sought
to investigate the possible mechanisms by which human
MSCs promote re-vascularization and prevent follicle
loss in xenografted ovarian tissues.
Angiogenesis is a multi-step process that involves the
survival, proliferation, migration, and differentiation of
endothelial cells, as well as tube formation and matur-
ation. In recent years, several studies have used different
approaches to investigate the mechanisms by which
MSCs facilitate angiogenesis; however, no consistent
conclusion has been reached. Some studies have indi-
cated that MSCs are capable of differentiating into endo-
thelial cells, pericytes, or even vessel walls to support the
formation of blood vessels [14–16]. Other studies have
suggested that MSCs are capable of protecting endothe-
lial cells from apoptosis, including from oxidative stress-
related apoptosis in the initial phase of angiogenesis
[17]. Furthermore, in addition to the early steps of
angiogenesis, such as endothelial cell proliferation,
MSCs have been reported to support the late phases of
angiogenesis, including blood vessel maturation [18, 19].
However, these proposed mechanistic explanations are
still debated. Conflicting data have shown that morpho-
logical and ultrastructural evidence of MSC differenti-
ation into endothelial cells or blood vessel wall
structures in vivo is uncommon. In addition, the integra-
tion of the transplanted MSCs into host blood vessels
has not been observed in animal studies [20].
In the past several years, research has focused on the
secretion-based paracrine regulatory role of MSCs.
Studies have shown that MSCs can establish a pro-
angiogenic microenvironment by persistently secreting
bioactive molecules that promote angiogenesis and
microvascular network formation [21]. Furthermore,
accumulating reports have suggested that the thera-
peutic potential of MSCs is largely dependent on their
secretory capacity rather than on their differentiation
capacity [22]. Studies of MSC secretion profiles have
shown that some pro-angiogenic cytokines, such as
VEGF, MCP-1 and FGF-2, can be detected in the condi-
tioned medium of MSCs [23]. However, the composition
of the profile of secreted molecules under different con-
ditions varies greatly, leading to differences in angiogenic
capacities [24]. For example, it has been reported that
under hypoxic conditions, the secretion of pro-
angiogenic factors can be significantly increased [25].
Due to these variations and the limited knowledge re-
garding the cytokine production of MSCs following
transplantation (a hypoxic condition), determining the
paracrine profiles and identifying the key secreted cyto-
kines in MSCs co-transplanted with ovarian tissues are
essential steps before further (pre)clinical studies can be
performed. Therefore, in the present study, we designed
an antibody-based cytokine microarray to investigate the
expression profiles of angiogenesis-related proteins in
frozen-thawed ovarian tissues co-transplanted with
MSCs. We found that a panel of proteins, including
angiogenin (ANG), was significantly up-regulated.
Hence, we sought to suppress ANG secretion in MSCs
via RNAi with an ANG-specific short-hairpin RNA
(shANG) or using ANG monoclonal antibodies to
explore the role of ANG in angiogenesis and follicle
survival induced by MSCs in ovarian transplantation.
Methods
Identification and isolation of human MSCs
The protocols for the collection of human MSCs and
ovarian samples were approved by the Ethics Committee
of the Peking University Third Hospital. Informed con-
sent was obtained from all subjects. Human MSCs were
isolated by density gradient centrifugation (Additional
file 1: Figure S1). The detailed methods were described
previously [26]. Human MSCs were isolated from the
bone marrow of a healthy female (age: 28 years old) who
underwent bone marrow harvesting for allogeneic bone
marrow transplantation at our hospital. Human MSCs
were cultured in alpha minimum essential Eagle’s
medium (α-MEM) supplemented with 20% human
serum albumin (Life Technologies, Carlsbad, CA), L-
glutamine and penicillin-streptomycin (Invitrogen, Life
Technologies, Grand Island, NY) and used for experi-
ments during passages 3 to 8. For identification, the
MSCs were stained with antibodies against CD34, CD44,
CD45, CD19, CD90, and CD105 (Biolegend, San Diego,
CA). The detail information about surface marker selec-
tion and stemness potential characterization of human
MSCs were provided previously [26].
Lentivirus production and infection
An ANG-specific short-hairpin RNAi (shANG) was syn-
thesized and cloned into a lentiviral GV248 vector (Gen-
echem, China). The sequences for RNAi were designed
to knock down the gene expression of ANG (shANG) or
were control particles (shCTRL) and were obtained
using the shRNA library of the RNAi Codex
(www.codex.cshl.edu).
The target sequences were as follows: shANG: 5′- CC
ACTTGGATCAGTCAATT -3′ and shCTRL: 5′-AAC
AGTCGCGTTTGCTACTTT-3′. Lentivirus preparation,
infection and selection were performed according to the
technical manual for the vector.
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Quantitative real-time PCR and ELISA
Total RNA was extracted from MSCs transfected with
shANG or shCTRL using a Total RNA Purification Plus
Kit (Norgen, Canada), according to the manufacturer’s
instructions. A total of 1.0 μg of RNA was reverse-
transcribed using the SuperScript III First-strand Synthe-
sis System. PCR amplification was carried out in an ABI
7500 Detection System using Power SYBR (Applied Bio-
systems, Carlsbad, CA) under the following conditions:
50 °C for 2 min; 95 °C for 2 min; and 40 cycles of 95 °C
for 15 s, 60 °C for 15 sec, and 72 °C for 1 min. GAPDH
was used as a reference gene for normalization. The
level of ANG mRNA expression was calculated using the
following formula: 2(ΔCt Test – ΔCt Control). The Ct of
ANG was compared with that of the internal control
GAPDH gene.
The primer sequences used for PCR were as follows:
GAPDH sense: 5′- TGACTTCAACAGCGACACCCA
-3′ and antisense: 5′- CACCCTGTTGCTGTAGCCA
AA -3′; ANG sense: 5′- CCTCCATGCCAGTACCGAG
-3′ and antisense: 5′- GGACGACGGAAAATTGAC
TGA -3′.
We used an ELISA kit (R&D, Abingdon, UK) for the
quantitative measurement of human ANG in the condi-
tioned media of MSCs transfected with specific shANG
or shCTRL after 24 h of culture. MSCs were plated on a
6-well plate at a density of 105 cells/well. ELISAs were
performed according to the manufacturer’s instructions.
Each sample was analyzed in triplicate.
Collection and treatment of human ovarian tissue
The use of human ovarian tissues was reviewed and
approved by the ethics committee of Peking University
(registration number: 2009005). Human ovarian tissue
was obtained from a 26-year-old female patient who
underwent gender reassignment surgery. One biopsy
from each ovary was obtained and cut into small pieces
after removing the medulla tissues. The ovarian tissues
were cryopreserved and thawed as previously described
[26]. Briefly, the ovarian tissue was transported from the
operating room to the laboratory in Leibovitz’s L-15
medium (Invitrogen, Carlsbad, CA) supplemented with
1% human serum albumin (Life Technologies, Carlsbad,
CA), 100 IU/mL penicillin (Sigma, St. Louis, MO) and
100 μg/mL streptomycin (Sigma, St. Louis, MO). After
enucleating the medulla with surgical scissors and a scal-
pel, the ovarian cortical tissues were manually cut into
small pieces with a size of 5 mm × 5 mm × 1 mm
(thickness).
Two slices of ovarian cortical tissues were placed in a
1.8-mL cryovial (Nunc, Roskilde, Denmark) containing
1 mL of 1.5 mol/L DMSO (Sigma-Aldrich, St. Louis,
MO), 0.1 mol/L sucrose (Sigma-Aldrich, St. Louis, MO)
and 10% HSA (Life Technologies, Carlsbad, CA) in
Leibovitz medium. After 30 min of exposure to the cryo-
protective agent at 4 °C, the cryovial was transferred to a
program freezer (Biomed Freezer Kryo 10, series II;
Planer, Middlesex, UK). The freezing and thawing proce-
dures were carried out according to the techniques
described by Andersen [27].
Ovarian transplantation in severe combined immune
deficiency mice
All animal procedures were approved by the Institu-
tional Animal Care and Use Committee of the Peking
University Third Hospital. A total of 30 8-week-old
female ovariectomized mice with severe combined
immune deficiency (SCID) (Animal Center of Medical
College of Peking University) were used in the study.
Consistently with previous reports [13, 28, 29], each
ovarian fragment was co-transplanted with 5 × 105 MSCs
in our study,.
For the array analysis, 6 mice were randomly assigned
to one of 2 groups: (1) Graft +MSC group: each ovarian
fragment was transplanted with 5 × 105 MSCs packaged
in 10 μL of Matrigel (Corning, USA); and (2) Graft
group (control): each ovarian fragment was transplanted
in 10 μL of Matrigel. The grafts were retrieved and rap-
idly frozen in liquid nitrogen for cytokine array analyses
7 days after transplantation.
For the shRNA blockade experiment, 12 mice were
divided into 4 equal groups: (1) Graft group: each ovar-
ian fragment was transplanted with 10 μL of Matrigel;
(2) Graft +MSC group: each ovarian fragment was trans-
planted with 5 × 105 MSCs packaged in 10 μL of Matri-
gel; (3) Graft + shCTRL MSC group: each ovarian
fragment was transplanted with 5 × 105 shCTRL- trans-
fected MSCs packaged in 10 μL of Matrigel; and (4)
Graft + shANG MSC group: each ovarian fragment was
transplanted with 5 × 105 stably shANG-transfected
MSCs packaged in 10 μL of Matrigel.
For the antibody blockade experiment, 12 mice were
divided into 4 equal groups:
(1) Graft group: transplantation of ovarian tissues with
10 μL of Matrigel; (2) Graft +MSC group: each ovarian
fragment was transplanted with 5 × 105 MSCs packaged
in 10 μL of Matrigel; (3) Graft +MSC + Control antibody
(Ab) group: each ovarian fragment was transplanted with
5 × 105 MSCs with 200 μg/mL of a control isotype IgG
antibody (Thermo Fisher Scientific, Carlsbad, CA) pack-
aged in 10 μL of Matrigel; and (4) Graft +MSC + ANG
Ab group: each ovarian fragment was transplanted with
5 × 105 MSCs with 200 μg/mL of the ANG monoclonal
antibody 26-2 F (Millipore, Germany) packaged in 10 μL
of Matrigel.
The detailed transplantation procedure has been de-
scribed previously [13]. Briefly, before transplantation,
the SCID mice were anesthetized via intraperitoneal
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injection of 2,2,2-tribromoethyl alcohol (Sigma, St.
Louis, MO) and tertamyl alcohol (Sigma, St. Louis,
MO). Two skin incisions were made in the lower third
of the abdominal wall on both sides after sterilizing the
area. The ovarian tissues were randomly chosen and
xenografted into the subcutaneous interspace, where the
cortical side adhered to the skin and the medullar side
adhered to the fascia. Two pieces of ovarian tissue were
then placed in each mouse. The skin incisions were sub-
sequently closed with absorbable 5/0 Prolene (Ethicon,
Somerville, NJ). All procedures were performed under
aseptic conditions. The animals were euthanized via cer-
vical dislocation after 7 days (3 mice in each group).
Ovarian cortical tissues were retrieved and fixed in 4%
formaldehyde for histological and immunohistochemical
examination.
Human angiogenesis array
A human antibody-based array kit was purchased from
Raybiotech (Raybiotech Inc, Norcross GA); in the kit,
glass slides were printed as sub-arrays consisting of 42
antigen-specific antibodies against angiogenesis-related
factors. The antibody array was used according to the
manufacturer’s instructions. The results were normalized
to internal positive controls for comparison. Two repli-
cates per antibody were spotted, and the average of the
median signal intensity from each spot (minus local
background subtraction) was used for the calculation.
The arrays were visualized using ImageQuant LAS4000
software (GE Healthcare) and analyzed using ImageJ
(National Institutes of Health).
Assessment of ovarian histology
Ovarian histology was evaluated based on hematoxylin
and eosin (HE) staining. The detailed procedures have
been described previously [13]. After fixation, xeno-
grafted ovarian tissues were processed for routine paraf-
fin embedding, and 5-μm-thick serial sections were
prepared. One from every five serial sections was used
for HE staining, and follicles were counted in five ran-
domly selected fields at × 400 magnification. To avoid
counting follicles more than once, only follicles with a
visible nucleus were counted. Follicle stages were classi-
fied as previously described [30]. The number of primor-
dial follicles in each group was expressed as the sum of
the follicles in 25 different sections.
Immunohistochemistry and Immunofluorescence study
Immunohistochemistry was performed using the ABC
Staining System (Zhongshan Golden Bridge Biotechnol-
ogy, Inc., Beijing, China). The detailed procedures have
been described previously [31]. For CD-31 staining,
human fetal villus tissues (10-week-old) were used as a
positive control. For AC-3 staining, thawed human
ovaries (female, age: 21) were used as a positive control.
The primary antibody was omitted in the negative con-
trol. The follicles with positive staining (brown staining
in the cytoplasm/nucleus) and the total number of folli-
cles were counted in five random fields (×400) of each
section in 25 different sections in each sample. To evalu-
ate vascular density, CD31-positive vessels were counted
in five random fields (×400 magnification) of each
section and in 5 different sections from each sample.
Immunofluorescence staining of CD31 and Ki67 were
performed as described previously [32].
Statistical analysis
All experiments were repeated three times unless speci-
fied otherwise. Analyses were performed using SPSS
13.0 software (SPSS, Inc., Chicago, IL, USA). For the
microarray, qPCR and ELISA data, statistical significance
was determined with a two-tailed Student’s t test. The
vascular density, follicle count and AC-3 percentage data
were analyzed via one-way or two-way analysis of vari-
ance (ANOVA), followed by pairwise comparisons using
the LSD method. All P values were two-sided. A P value
< 0.05 was considered statistically significant.
Results
ANG levels are significantly increased upon
co-transplantation of MSCs with ovarian tissues
The characterization of MSCs was shown in Additional
file 2: Figure S2. The isolated MSCs were negative for
CD34, CD45, and CD19 and positive for CD44, CD90,
and CD105. IHC study showed scattered positive expres-
sion of CD90 and CD105 in the ovarian tissue co-
transplanted with MSCs (Additional file 3: Figure S3).
To investigate whether certain secreted factors were spe-
cifically increased in the co-transplanted ovarian tissues
and MSCs, we analyzed 42 angiogenesis-related proteins
via protein microarray analysis (Fig. 1). The results were
compared with the Graft group (xenografted ovarian
tissues only). In total, the expression levels of 37 pro-
teins were higher in the Graft +MSC group, whereas the
expression levels of 5 proteins were higher in the Graft
group. Twelve proteins were at least two-fold more
abundant in co-transplanted ovarian tissue and MSCs
than in solely ovarian grafts (Fig. 1b). The remaining
proteins exhibited non-significant changes. By contrast,
no proteins were at least twice as abundant in solely
ovarian grafts as in co-transplanted ovarian tissue and
MSCs. We were intrigued that ANG exhibited a marked
increase in expression (up to 4.49-fold) in co-
transplanted ovarian tissue and MSCs, particularly as it
has been reported that ANG plays an essential role in
endothelial cell proliferation and angiogenesis [33].
Although the expression of angiopoietin-2 was even
higher (by up to 5.76-fold), angiopoietin-2 has been
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associated with endothelial cell death and vascular re-
gression [34]. Therefore, we focused on ANG in our
subsequent experiments.
Blockade of ANG suppresses MSC-stimulated ovarian
angiogenesis
Because ANG was robustly increased in MSCs co-
transplanted with ovarian grafts, we speculated that
ANG might play a key role in angiogenesis and follicle
survival in MSCs co-transplanted with ovarian grafts. To
test our hypothesis, we specifically inhibited ANG func-
tion in MSCs using either shANG or an anti-ANG neu-
tralizing antibody. The results of RT-PCR indicated that
shANG significantly suppressed the mRNA expression
of ANG, with a 72.4% knockdown efficiency (P < 0.01,
Additional file 4: Figure S4A). In addition, secreted ANG
was measured in the cell culture media using a commer-
cial ELISA. As expected, a significantly lower secreted
ANG level was observed in the shANG-transfected
MSCs than in the shCTRL-transfected MSCs (P < 0.01,
Additional file 4: Figure S4B).
Ovarian angiogenesis in each group in the shRNA and
antibody blockade experiments was assessed via CD31
staining and microvascular density counts (Fig. 2a, c).
Similar to our previous study, by day 7, co-
transplantation of MSCs with the graft (Graft +MSC
group) had significantly promoted the density of CD31-
positive microvessels compared with the densities in the
Fig 1 Angiogenin level is significantly increased in co-transplanted of ovarian tissues and MSCs. a List of antibodies against angiogenesis related
cytokine factors by RayBiotech human antibody array; b Comparison of the panel of protein expression profiles in ovarian graft and MSCs co-
transplantation (Graft + MSC group) versus Graft group. (Left) Heat maps were developed with the hierarchical clustering algorithm between the
two groups. For each protein, signals from all conditions were averaged to generate the baseline. Signals above baseline are red; signals below
baseline are green. The heat map key shows log2-fold changes from baseline. (Right) Lists of differential expressed protein that was abundant in
Graft + MSC group or in MSC group. MSC, mesenchymal stem cells. POS, positive control. NEG, negative control
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Graft group (Additional file 5: Figure S5) in both the
shRNA (6.23 ± 0.55 vs. 4.13 ± 0.61, respectively, P < 0.05,
Fig. 2b) and ANG antibody blockade experiments (6.97
± 0.59 vs. 4.43 ± 0.38, respectively, P < 0.05, Fig. 2d). In
the shRNA blockade experiment, the microvascular
density was significantly decreased in the Graft +MSC
shANG group (5.03 ± 0.51) compared with those of the
Graft +MSC (6.23 ± 0.55, P < 0.05, Fig. 2b) and Graft +
MSC shCTRL groups (6.47 ± 0.60, P < 0.05, Fig. 2b). This
finding showed that ovarian angiogenesis induced by
MSCs was significantly suppressed by shANG, most
likely due to the suppression of ANG secretion. Al-
though shCTRL did not suppress MSC-induced
angiogenesis, the microvascular density in the Graft +
MSC shCTRL groups (6.47 ± 0.60) was not signifi-
cantly different from that in the Graft + MSC groups
(6.23 ± 0.55, P = 0.63, Fig. 2b). In the antibody block-
ade experiment, we found that the microvascular
density was significantly decreased in the Graft +
MSC + ANG Ab group (5.2 ± 0.46) compared with
those in the Graft +MSC group (6.97 ± 0.59, P < 0.05,
Fig. 2d) and the Graft +MSC +CTRL Ab group (6.70 ±
0.80, P < 0.05, Fig. 2d), which showed that the ANG Ab
sufficiently blocked MSC-induced angiogenesis, probably
via the neutralization of ANG secretion. By contrast, the
CTRL IgG Ab had no influence on the effect of MSCs on
ovarian angiogenesis, as the microvascular density in the
Graft +MSC +CTRL Ab group (6.70 ± 0.80) was not
significantly different from that in the Graft +MSC group
(6.97 ± 0.59, P = 0.45, Fig. 2d).
Blockade of ANG neutralizes MSC-stimulated follicular
survival
Before transplantation, the average number of primodial
follicles in ovarian tissue is 63.17 ± 9.52. Next we exam-
ined the number of primordial follicles in xenografted
ovarian tissues after ANG blockade in MSCs using either
shRNA or a neutralizing antibody. Representative HE-
stained follicles from each group are shown in Fig. 3 and
Additional file 6: Figure S6. Consistent with our previous
study, the co-transplantation of MSCs with ovarian
tissues (Graft + MSC group) significantly increased the
follicle count compared with that of the Graft group
in both the shRNA (36.27 ± 2.85 vs. 27.13 ± 2.32,
respectively, P < 0.05, Fig. 3b) and antibody blockade
experiments (34.57 ± 1.60 vs. 26.73 ± 2.07, respectively,
P < 0.05, Fig. 3d). In the shRNA experiment, the num-
bers of primordial follicles in the Graft + MSC shANG
Fig 2 Angiogenin-blockade suppressed MSCs-stimulated ovarian angiogenesis. a Representative figures showing microvascular density of ovarian
tissues in shRNA blockage analysis, as determined by CD31 immunoactivity, at post-transplantation day-7 in each group. b Quantitative analysis
of microvascular densities between different groups in shRNA blockage analysis, c Representative figures showing microvascular density of ovarian
tissues in antibody blockage experiment, as determined by CD31 immunoactivity, at post-transplantation day-7 in each groups. d Quantitative
analysis of microvascular density between different groups in antibody blockage experiment. Data shown are means ± SEM of triplicates in a
representative experiment. MSC, mesenchymal stem cells; ANG, angiogenin; CTRL, control; Ab, antibody; shANG, ANG specific short hairpin RNA;
shCTRL, control short hairpin RNA, * P < 0.05. Scale bar = 100 μm
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group (29.27 ± 2.05) were significantly lower than those in
the Graft +MSC (36.27 ± 2.85, P < 0.05, Fig. 3b) and the
Graft +MSC shCTRL groups (35.03 ± 1.99, P < 0.05,
Fig. 3b). This result indicates that the suppression of ANG
secretion by shANG significantly neutralized the ability of
MSCs to enhance follicular survival. However, shCTRL
did not attenuate the effect of MSCs on the enhancement
of follicular survival, as the numbers of primordial follicles
in the Graft +MSC +CTRL Ab group (35.03 ± 1.99) was
not significantly different from that in the Graft +MSC
group (36.27 ± 2.85, Fig. 3b). In the antibody blockade ex-
periment, the number of primordial follicles in the
Graft + MSC + ANG Ab group (30.10 ± 2.43) was sig-
nificantly lower than those in the Graft + MSC (34.57
± 1.60, P < 0.05, Fig. 3d) and Graft + MSC + CTRL Ab
groups (35.40 ± 2.78, P < 0.05, Fig. 3d), indicating that
the suppression of ANG secretion by the ANG anti-
body significantly neutralized the ability of MSCs to
enhance follicular survival. However, the CTRL IgG
Ab did not have a neutralizing effect, as the number
of primordial follicles in the Graft + MSC + CTRL Ab
groups (35.40 ± 2.78) was not significantly different
from that in the Graft +MSC group (34.57 ± 1.60, P =
0.66, Fig. 3d).
Blockade of ANG increases follicular apoptosis after the
co-transplantation of MSCs
Active caspase 3 (AC-3) was used as a marker of apop-
tosis in IHC experiments, and representative images of
AC-3 expression in each group are presented in Fig. 4a
and c. Similar to our previous study, MSC co-
transplantation significantly reduced follicular apoptosis
in the Graft +MSC group compared with that in the
Graft group in both the shRNA (12.3 ± 2.5% vs. 18.7 ±
3.3%, respectively, P < 0.05. Fig. 4b) and antibody block-
ade experiments (9.7 ± 3.4% vs. 20.0 ± 3.1%, respectively,
P < 0.05. Fig. 4d). We hypothesized that ANG blockade
may increase follicular apoptosis with co-transplantation
of MSCs. Indeed, in the shRNA blockade experiment,
shANG significantly increased follicular apoptosis, as a
significantly elevated number of AC-3-positive primor-
dial follicles was observed in the Graft +MSC shANG
group (17.2 ± 2.4%) in comparison to the number in the
Graft +MSC (12.3 ± 2.5%, P < 0.05. Fig 4b) and the Graft
+ shCTRL MSC groups (11.2 ± 2.0%, P < 0.05. Fig 4b). It
is not surprising that shCTRL did not affect follicular
apoptosis in xenografted ovarian tissues after the co-
transplantation of MSCs, as the follicular apoptosis rate
in the Graft +MSC shCTRL group (11.2 ± 2.0%) was not
Fig 3 Blockade of angiogenin neutralized MSC-stimulated follicular survival after co-transplantation of MSCs. a Representative images of HE-stained
section showing number of primodial follicles in ovarian tissue at post-transplant day-7 of each group in the shANG blockage experiment. b Quantitative
analysis of follicular numbers in different groups in shANG blockage experiment. c Representative images of HE-stained section showing number of
primodial follicles in ovarian tissue at post-transplant day-7 of each group in antibody blockage experiment. d Quantitative analysis of primodial follicular
numbers in different groups in antibody blockage experiment. Data shown are means ± SEM of triplicates in a representative experiment.
MSC, mesenchymal stem cells; ANG, angiogenin; CTRL, control; Ab, antibody; shANG, ANG specific short hairpin RNA; shCTRL, control short
hairpin RNA, * P < 0.05. Scale bar = 50 μm
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significantly different from that of the Graft +MSC
group (12.3 ± 2.5%, P = 0.61, Fig. 4b).
In the antibody blockade experiment, the ANG anti-
body significantly increased follicular apoptosis, and sig-
nificantly elevated numbers of AC-3-positive follicles
were observed in the Graft +MSC + ANG Ab group
(17.9 ± 2.1%) compared with the numbers in the Graft +
MSC group (9.7 ± 3.4%, P < 0.05. Fig 4d) and the Graft +
MSC + CTRL Ab group (11.5 ± 2.6%, P < 0.05. Fig 4d). It
is not surprising that the CTRL IgG Ab did not affect
follicular apoptosis in xenografted ovarian tissues after
the co-transplantation of MSCs; the follicular apoptosis
rate in the Graft +MSC + CTRL Ab group (11.5 ± 2.6%)
was not significantly different from that of the Graft +
MSC group (9.7 ± 3.4%, P = 0.47, Fig. 4d).
Discussion
Our study highlights several important findings. The
first is that the expression levels of a panel of proteins,
including ANG, were significantly increased upon the
co-transplantation of MSCs with ovarian tissues. The
second is that the blockade of ANG using either the spe-
cific shANG or an ANG neutralizing antibody could
suppress MSC-induced ovarian angiogenesis and follicle
survival. These results indicated that MSC-derived ANG
induced angiogenesis and follicle survival in xenografted
human ovarian tissues. Our study is the first to demon-
strate the crucial role of ANG in mediating the pro-
angiogenic effect of MSCs co-transplanted with ovarian
tissue, and these results provide a theoretical basis for
further research on and the application of MSCs in ovar-
ian tissue transplantation.
The ability of MSCs to release paracrine factors with
pro-angiogenic functions has been observed in many
studies. Umbilical cord MSC-derived microvesicles con-
taining several angiogenic factors, including EGF and
VEGF, contribute to the pro-angiogenic effect of MSCs
[35]. Placental chorionic villus MSCs showing a high
capacity to release angiogenic factors, including VEGF
and hepatocyte growth factor, have been found to con-
tribute to the functional improvement of ischemic hind
limbs of nude mice after transplantation [36]. Pre-
clinical and clinical studies have also shown that MSCs
can augment cardiac function upon implantation into
the ischemic/infarcted myocardium [37, 38]. These stud-
ies have suggested that pro-angiogenic factors released
by MSCs could stimulate angiogenesis and increase
regional perfusion. In our model of MSC and ovarian
tissue co-transplantation, MSCs were packaged in Matri-
gel surrounding the ovarian graft, providing a suitable
Fig 4 Blockade of angiogenin increased primordial follicular apoptosis after co-transplantation of MSC. a Representative images showing primordial
follicular apoptosis as determined by AC3 staining of ovarian tissues at post-transplantation day-7 in different groups in shANG blockage experiment.
b Quantitative analysis of primordial follicular apoptosis between different groups in shANG blockage experiment. c Representative images showing
primordial follicular apoptosis as determined by AC3 staining of ovarian tissues at post-transplantation day-7 in different groups in antibody blockage
experiment. d Quantitative analysis of primordial follicular apoptosis between different groups in antibody blockage experiment. Data shown are
means ± SEM of triplicates in a representative experiment. MSC, mesenchymal stem cells; ANG, angiogenin; Ab, antibody, shANG, ANG specific short
hairpin RNA, shCTRL, control short hairpin RNA, * P < 0.05. Scale bar = 50 μm
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microenvironment for the release of pro-angiogenic pro-
teins. Antibody-based cytokine array technology offers a
novel approach for gaining insight into changes in pro-
tein expression profiles. Our array results reflected the
secretion profiles of MSCs co-transplanted with ovarian
tissues. Further analyses showed that despite the variety
of angiogenic factors in the paracrine profiles of MSCs,
the targeted inhibition of ANG had a substantial effect
on the angiogenic ability of MSCs in ovarian transplant-
ation. One possible explanation for this finding is that,
as previously reported, the presence of ANG could be
essential for other angiogenic factors, including VEGF
and bFGF, to functionally induce angiogenesis [33].
ANG, also known as ribonuclease 5, is a secreted
protein. In the past several years, studies have shown that
ANG has angiogenic [39], neurogenic [40], and immune-
regulatory [41] functions. Several pro-angiogenic factors,
including ANG, have been isolated from the follicular
fluid, and a positive association with follicular growth has
also been suggested [42–45]. The present study suggests a
critical role for ANG in establishing vascularization and
promoting follicle survival in ovarian grafts co-
transplanted with MSCs. It should be acknowledged that
angiogenesis is a complicated process and that the pro-
angiogenic effects of MSCs involve a variety of secreted
factors. In our study, after the blockade of ANG, the pro-
angiogenic effect of MSCs was attenuated. This inhibition
was not complete, as the microvascular density after either
shRNA or antibody blockade was still higher than in the
Graft group; however, this difference did not reach statis-
tical significance. This phenomenon might be explained
by the fact that other factors independent of ANG may
also be involved in the pro-angiogenic effect of MSCs.
Interestingly, the array result suggests induced expression
of both MMPs and TIMP-2 in MSCs transplanted ovary.
MMPs were speculated to be induced by the hypoxic con-
dition of ovarian grafts. Since TIMP-2 is an known antag-
onist of MMPs and endogenous inhibitor of angiogenesis,
the induction of TIMP-2 may suppress excess formation
of microvessels and non-functional microvessels. Add-
itionally, it is worth noting that other secreted factors that
have been reported to exhibit an anti-angiogenic capacity,
such as angiopoietin-2, were significantly increased, as
well, according to our microarray results. This result
might be attributed to the equilibrium between angiogenic
stimulators and inhibitors in the angiogenically balanced
microenvironment established by the MSCs, which
precisely regulates the rate of blood vessel formation.
Ischemia–reperfusion injury after ovarian tissue trans-
plantation has been shown to lead to considerable
follicular loss and to shorten the duration of ovarian
function [46]. Graft angiogenesis following ovarian tissue
transplantation is critical for graft viability. The re-
establishment of vascularization in xenografted ovarian
tissues is observed within 48 h of grafting, and this
process lasts for approximately 1 week [47]. In an ovar-
ian autograft study using mice, blood perfusion could be
observed on day 3 after transplantation, and functional
vessels could be detected on day 7 post-transplantation
[48, 49]. Similarly, in a human study, microvessels
started to form 48 h post-transplantation, whereas func-
tional vessels required approximately 7 days to generate;
thus, 7 days was proposed as an important landmark
after transplantation [31, 50]. Therefore, in the present
study, xenografted ovarian tissues were retrieved on day
7 post-transplantation. We selected the subcutaneous
route for transplantation in this study since the subcuta-
neous areas of the abdominal wall have been reported to
be one of the most preferable options for follicular
development in ovarian transplantation [51, 52].
In recent years, numerous studies have focused on in-
terventions to facilitate angiogenesis in transplanted
ovarian tissue. Labied et al. [53] suggested that VEGF111
could stimulate vascular endothelial cell proliferation
and functional angiogenesis, thereby increasing the
viability of the ovarian cortex. Experimental data have
also shown that basic fibroblast growth factor and fibrin
hydrogel can improve angiogenesis and promote follicle
development in mice [31]. However, none of these fac-
tors have been successfully utilized in a clinical setting
thus far. Further investigation of methods for improving
angiogenesis in ovarian tissue transplantation is re-
quired. Our previous study showed that MSCs show
promise for the improvement of ovarian tissue trans-
plantation and follicle growth [13, 26]. Although MSCs
can be obtained from bone marrow, readily cultured and
preserved for future use, further research is needed to
develop methods for their use. Our findings suggest
mechanistic explanations for the angiogenic effect of
MSCs in ovarian transplantation, providing important
information for further applications.
Previous studies have indicated that the therapeutic
application of secreted molecules as a possible replace-
ment for stem cells might lead to the development of
safe and effective therapeutic strategies with predictable
outcomes [22]. Therefore, practical interventions to
facilitate angiogenesis, including treatment with exogen-
ous angiogenic factors, might be promising in clinical
settings, as this approach will circumvent the ethical and
safety constraints associated with the direct use of
human MSCs. In our preliminary study, the treatment of
xenografted ovarian tissues with exogenous recombinant
ANG enhanced angiogenesis, even without MSCs (data
not shown). However, due to the scarcity of human
ovarian tissue samples available for research, we were
unable to comprehensively investigate the outcomes of
ovarian transplantation through treatment with exogen-
ous recombinant ANG protein. Additional studies of the
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use of human ovarian cortical grafts with long-term
ANG treatment are necessary to elucidate the effects
and functional mechanism of ANG in mediating the
angiogenesis of xenografted ovarian tissue. Continuing
research on this topic will help elucidate the efficacy and
safety of exogenous ANG intervention in ovarian tissue
transplantation in clinical settings.
Conclusions
In conclusion, our findings are the first to suggest that
MSCs mediate angiogenesis and follicle survival in xeno-
grafted human ovarian tissue through ANG. Our results
provide a theoretical basis and important information
for the further application of MSCs in ovarian tissue
transplantation and could eventually aid patients in
preserving fertility.
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Additional file 1: Figure S1. Isolation of MSCs from human bone
marrow tissues by density gradient centrifugation. (JPG 727 kb)
Additional file 2: Figure S2. Identification of MSCs by Flow Cytometry.
(A) Representative histogram of FACS results showing the MSCs surface
marker profile. The blue peak indicated the specific antibodies: CD34,
CD45, CD19, negative cocktail (including CD44, CD90 and CD105). The
red peak represented the isotope antibodies. (B) Positive expression of
CD34, CD45, CD19 and negative cocktail (including CD44, CD90 and
CD105) in five individuals as examined by flow cytometry was
expressed as mean ± SD. The proportion of cells expressing CD44,
CD90, CD105 and negative cocktail, which were analyzed from 5
independent samples, were 96.6% ± 2.1%, 96.4% ± 2.2%, 97.2% ± 2.0%
and 2.9% ± 0.6%. (JPG 418 kb)
Additional file 3: Figure S3. Representative images showing expression
of CD90 and CD105 in ovarian sections after co-transplantation of MSCs
in both high and low magnification. MSC, mesenchymal stem cells. Scale
bar = 200 μm in A and C, Scale bar = 50 μm in B and D. (JPG 453 kb)
Additional file 4: Figure S4. The MSC clones stably knocking down
ANG were identified and verified on qPCR and ELISA analysis. A) Results
of quantitative PCR showed a significant knock-down of ANG mRNA
expression in the shANG transfected MSCs (n = 3). B) Secreted ANG
protein level in the shANG and shCTRL transfected MSCs groups were
determined by ELISA (n = 3). Data are shown as means ± SEM of
triplicates in a representative experiment. MSC, mesenchymal stem
cells; ANG, angiogenin; shANG, ANG specific short hairpin RNA,
shCTRL: control short hairpin RNA, * P < 0.01. (TIF 7881 kb)
Additional file 5: Figure S5. Representative images showing triple
staining of Ki67, DAPI and CD31 in ovarian graft with or without
co-transplantation of MSCs. Vasculature is shown in red, cell nuclei
are shown in blue and Ki67 positive nuclei are shown in green.
Scale bar = 50 μm. (JPG 299 kb)
Additional file 6: Figure S6. Representative images showing HE
staining of ovarian sections in ovarian graft with or without
co-transplantation of MSCs in both high and low magnification.
MSC, mesenchymal stem cells. Scale bar = 200 μm in A and C,
Scale bar = 50 μm in B and D. (JPG 507 kb)
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